Positive new Phase III data for Novo Nordisk’s denecimig

Danish pharma major Novo Nordisk (NOV: N) on Saturday unveiled new data from the Phase III FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig (Mim8) subcutaneous prophylaxis in children, adolescents, and adults with hemophilia A, with or without inhibitors, across a of dosing frequencies including once-monthly, once-every range -two-weeks, and once-weekly administration.

These results and other data across Novo Nordisk’s hemophilia portfolio were presented at the International Society on Thrombosis and Hemostasis (ISTH) Congress in Paris.